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Maintenance treatment with an inhaled corticosteroid (ICS) and a long-acting b2-agonist (LABA) is
recommended for patients whose asthma is not controlled with a low-to-moderate dose of ICS alone; a
separate reliever medication is used on an as-needed basis. The Gaining Optimal Asthma ControL (GOAL)
study demonstrated that salmeterol/ﬂuticasone maintenance treatment can improve asthma control and
reduce future risk compared with ﬂuticasone alone, although the dose escalation design of this study
meant that most patients treated with salmeterol/ﬂuticasone were receiving the highest dose of ICS at
the end of the study. Similarly, budesonide/formoterol maintenance therapy improved asthma control
and reduced future risk compared with budesonide alone in the Formoterol and Corticosteroids Estab-
lishing Therapy (FACET) study. An alternative approach to asthma management is to use an ICS/LABA for
both maintenance and reliever therapy. A large body of clinical evidence has shown that the use of
budesonide/formoterol in this way improves both current control and reduces future risk compared with
ICS/LABA plus as-needed short-acting b2-agonist (SABA), even when patients receive lower maintenance
doses of ICS as part of the maintenance and reliever therapy regimen. In addition, one study has shown
that beclometasone/formoterol maintenance and reliever therapy reduces exacerbations more effectively
than beclometasone/formoterol plus as-needed SABA. The use of ICS/LABA as both maintenance and
reliever therapy ensures that an increase in reliever use in response to worsening symptoms is auto-
matically matched by an increase in ICS.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Asthma is a major public health problem worldwide, which,
when uncontrolled, can severely limit the patient's daily life [1].
The primary aim of treatment is to achieve and maintain overall
asthma control by reducing the severity of current symptoms and
minimising future risk [1,2]. Current control is characterised by the
frequency of symptoms, use of reliever medication, lung function
and physical activity limitation. Future risk includes longer-term
factors such as the frequency of exacerbations, decline in lung
function over time and adverse effects of treatment [1,2].
Maintenance treatment with an ICS and a LABA, either sepa-
rately or as a ﬁxed-dose formulation, is recommended for patients
whose asthma is not adequately controlled when treated with a
low-to-moderate dose of ICS alone; a separate reliever inhaler is
used on an as-needed basis [1]. Many different ICS/LABA ﬁxed-dose
combinations are available for use in patients with asthma. For
example, budesonide/formoterol and salmeterol/ﬂuticasone pro-
pionate (from herein referred to as ﬂuticasone) have been available
for many years and their efﬁcacy in patients with asthma has been
demonstrated in several large-scale randomised trials [3,4]. More
recently, beclometasone/formoterol, ﬂuticasone/formoterol and
vilanterol/ﬂuticasone furoate have been approved for use in adult
patients with asthma [5e9]. Mometasone/formoterol is also avail-
able in the USA [10].
An alternative approach to the management of asthma is to use
budesonide/formoterol or beclometasone/formoterol as both
maintenance and reliever therapy, providing patients with a
simpliﬁed treatment regimen that requires only a single inhaler. By
employing this treatment strategy, patients receive ICS in addition
to a fast-acting bronchodilator whenever they require reliever
medication, meaning that inﬂammation can be targeted when
symptoms increase [11]. This approach has shown utility in the
management of asthma [12e19], and is recommended by GINA and
approved for use in Europe and a number of other countries around
the world [1].
In this article, the role of ICS/LABA in themanagement of asthmaTable 1
Overview of study design and patient numbers in the FACET [3] and GOAL [4] st
Parameter FACET [3]
Patients, n 852
Run-in period
Treatment received BUD 800 mg
Duration, weeks 4
Study duration, months 12
Study interventionsc 1. BUD 100 mg þ placebo
2. BUD 100 mg þ FORM 12
3. BUD 400 mg þ placebo
4. BUD 400 mg þ FORM 12
Dosing frequency Twice daily
All BUD and FORM doses are shown as metered dose.
BUD, budesonide; FACET, Formoterol and Corticosteroids Establishing Therapy; F
ICS, inhaled corticosteroid; SAL, salmeterol.
a Completed phase 1: dose escalation phase in which treatment was stepped u
study drug reached (SAL/FLU 50/500 mg or FLU 500 mg bd).
b Completed phase 2: remained on dose at which they achieved total asthma
month double-blind treatment period.
c Patients were randomised to one of the treatment arms.will be reviewed, considering both current control and future risk.
We will summarise results from the landmark GOAL and FACET
studies, which demonstrated the advantages of adding a LABA to an
ICS by comparing salmeterol/ﬂuticasone or budesonide/formoterol
with ICS alone [3,4]. We will then explain how data from the
budesonide/formoterol and beclometasone/formoterol mainte-
nance and reliever therapy studies [12e17,19], in particular, expand
upon the ﬁndings of both GOAL and FACET.
2. Achieving current control and reducing future risk: the
ICS/LABA approach
In patients whose asthma is not well controlled with a low dose
of ICS, there are two possible strategies that can be used to improve
control: increasing the dose of ICS or adding a LABA [1]. However,
concern has been expressed that the addition of a LABA to a low
dose of ICS may enhance current control but mask inﬂammation,
therefore increasing future risk [20,21].
In the FACET study, patients who had stable asthma after a run-
in period were randomised to receive budesonide (at a low or high
dose) in combination with either formoterol or placebo (Table 1)
[3]. Patients were eligible for inclusion if they had been diagnosed
with asthma for at least six months and had been treated with an
ICS for at least three months, although patients receiving high
doses of ICS at baseline were excluded. The addition of formoterol
to budesonide enhanced current control compared with an
increased dose of budesonide. Indeed, the addition of formoterol to
budesonide was associated with a signiﬁcantly higher number of
episode-free days and greater improvements in day and night-time
symptom scores comparedwith the same dose of budesonide alone
(p ¼ 0.001). While the mean number of episode-free days was
signiﬁcantly increased with the addition of formoterol 12 mg to
twice-daily budesonide 100 mg (metered dose), there was no sig-
niﬁcant increase with twice-daily budesonide 400 mg alone
(Fig. 1A). In contrast, although the addition of formoterol to a low
dose of budesonide decreased future risk by reducing the rate of
severe exacerbations by 26%, a greater reduction was achievedudies.
GOAL [4]
3039a/2890b
Usual dose (if any) of ICS
4
12
mg
mg
1. FLU (100, 250 or 500 mg)
2. SAL/FLU (50/100, 50/250 or 50/500 mg)
Twice daily
LU, ﬂuticasone; FORM, formoterol; GOAL, Gaining Optimal Asthma ControL;
p every 12 weeks until total asthma control was achieved or highest dose of
control or the maximum dose of study medication until the end of the 12-
Fig. 1. Mean episode-free days (A) and number of severe exacerbations (B) among patients treated with twice-daily budesonide or budesonide/formoterol in FACET [3]. a Days with
no symptoms or rescue medication use and PEF >80% of baseline value. BUD, budesonide; FACET, Formoterol and Corticosteroids Establishing Therapy; FORM, formoterol; PEF, peak
expiratory ﬂow.
Fig. 2. Adjusted mean change from baseline in mean overall AQLQ score (A) and mean exacerbation rate (B) among patients treated with twice-daily ﬂuticasone or salmeterol/
ﬂuticasone in GOAL, stratiﬁed by pre-study ICS dose [4]. a Strata were based on ICS dose in the 6 months before screening; stratum 1, no ICS; stratum 2, 500 mg of beclometasone
dipropionate daily or equivalent; stratum 3, >500 mg to 1000 mg of beclometasone dipropionate daily or equivalent. AQLQ, Asthma Quality of Life Questionnaire; FLU, ﬂuticasone;
GOAL, Gaining Optimal Asthma ControL; ICS, inhaled corticosteroid; SAL, salmeterol.
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100 mg to 400 mg (Fig. 1B) [3].
In the GOAL study, patients were randomised to salmeterol/
ﬂuticasone or ﬂuticasone alone if they did not achieve at least two
well-controlled weeks in a four-week run-in period (Table 1) [4].
Patients were stratiﬁed by their pre-study ICS dose (stratum 1, no
ICS; stratum 2, 500 mg of beclometasone dipropionate daily or
equivalent; stratum 3, >500 mg to 1000 mg of beclometasone
dipropionate daily or equivalent). The study was split into two
phases; a dose-escalation phase followed by a phase during which
patients remained on their maximum dose of treatment. The
addition of salmeterol to ﬂuticasone improved health status and
signiﬁcantly reduced the exacerbation rate compared with ﬂuti-
casone alone (Fig. 2A and B), suggesting that salmeterol contributes
to improved current control and reduced future risk. However, thedesign of this study meant that is was not possible to determine
whether the addition of salmeterol to ﬂuticasone was more bene-
ﬁcial than increasing the dose of ﬂuticasone alone.
3. Achieving current control and reducing future risk:
limitations of aiming for total control
In the GOAL study, signiﬁcantly more patients treated with
salmeterol/ﬂuticasone achieved total asthma control, deﬁned as
achievement of 7 out of 8 weeks with no exacerbations, no night-
time awakening, morning peak expiratory ﬂow 80% predicted
every day, no symptoms, no need for rescue b2-agonist use, no
emergency room visits and no treatment-related adverse events
requiring a change in asthma therapy, than those receiving ﬂuti-
casone alone [4]. However, total asthma control was still only
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terol/ﬂuticasone. Interestingly, many of these patients achieved
total asthma control at the lowest dose of ICS (100 mg bd for strata 1
and 2; 250 mg bd for stratum 3), despite the majority of patients
(68%) who were treated with salmeterol/ﬂuticasone receiving the
highest dose of ﬂuticasone at the end of the study. The results of
this study therefore bring into question the beneﬁts of increasing
the maintenance dose of ICS until total control is achieved, espe-
cially as the lack of a down-titration plan in this study meant that
many patients received the highest dose of ICS for prolonged pe-
riods of time without achieving total asthma control [4]. Interest-
ingly, the results of the FACET study do suggest that a higher dose of
ICS may be advantageous for patients receiving ICS/LABA mainte-
nance treatment, as an increase in dose of ICS was associated with a
reduction in future exacerbation risk [3]. However, 34% of patients
still experienced severe exacerbations despite being treated with
the highest dose of budesonide/formoterol (400/12 mg bd; metered
dose) in this study (Fig. 1B).
The beneﬁt of increasing the maintenance dose of ICS has been
investigated in other studies [22,23]. In one study, 61 patients with
poorly controlled asthma were treated with budesonide at a
delivered dose of either 2560 mg or 1280 mg daily, in order to assess
whether asthma outcomes were improvedwhen ICS treatment was
started at the higher dose [22]. Down-titration of the ICS dose was
allowed after 16 weeks in patients whose asthma was controlled. A
starting dose of 1280 mg was found to be sufﬁcient to achieve
optimal asthma control, and there was no signiﬁcant improvement
in airway hyper-responsiveness for patients treated with budeso-
nide 2560 mg compared with the lower dose (p ¼ 0.7). However,
airway hyper-responsiveness did reach normal levels signiﬁcantly
more rapidly when patients were treated with budesonide 2560 mg
(p ¼ 0.03) [22]. In another study, patients with well-controlled
asthma were randomised to receive twice-daily salmeterol/ﬂuti-
casone at a dose of either 50/250 mg or 50/500 mg [23]. Improve-
ments in airway hyper-responsiveness were again more rapid in
patients receiving the higher dose of ICS, although this difference
was not statistically signiﬁcant. However, over the last eight weeks
of randomised treatment, the lower dose of ICS was sufﬁcient to
maintain well-controlled asthma and there were no signiﬁcant
differences between the two groups. Interestingly, other studies
have shown that an increased dose of ICS may be necessary to
reduce airway inﬂammation in patients with asthma [24e26]. In
one study, a signiﬁcantly smaller reduction in sputum eosinophils
was observed for patients who were treated with budesonide plus
formoterol compared with a four-fold higher dose of budesonide
alone (p < 0.001) [24]. In another study, treatment with budeso-
nide/formoterol was associated with a greater increase in sputum
eosinophils compared with a four-fold higher dose of budesonide
(3.41% vs. 1.74%), although this was not found to be statistically
signiﬁcant [25].
4. Achieving current control and reducing future risk: ICS/
LABA maintenance and reliever therapy
An alternative strategy to asthma management is to use ICS/
LABA as both maintenance and reliever therapy, and because of its
rapid onset of action, formoterol is suitable for use in this way in
combination with budesonide or beclometasone [27]. Indeed,
budesonide/formoterol maintenance and reliever therapy has been
investigated in several clinical trials and real-world studies
[12e18,28e31], and has a similar efﬁcacy and safety proﬁle to
salbutamol over a period of 3 h in the management of acute
bronchoconstriction in patients with asthma; its bronchodilator
activity is apparent oneminute after treatment [32,33]. There is less
evidence for the use of beclometasone/formoterol for maintenanceand relief, but this regimen was found to be more effective at
reducing asthma exacerbations than beclometasone/formoterol
plus as-needed salbutamol in one trial [19]. Consequently, the use
of budesonide/formoterol or beclometasone/formoterol mainte-
nance and reliever therapy is recommended in global asthma
treatment guidelines as an alternative to treatment with an ICS/
LABA plus a separate reliever medication [1].
4.1. ICS/LABA maintenance and reliever therapy: beyond FACET and
GOAL
The use of budesonide/formoterol as maintenance and reliever
therapy has been compared with all alternative standard treatment
strategies in patients with moderate-to-severe asthma [12e17]. In
particular, the STAY [14], COMPASS [16] and AHEAD [17] studies
built on GOAL and FACET by comparing budesonide/formoterol
maintenance and reliever therapy with two different doses of
budesonide/formoterol plus SABA, budesonide plus SABA and sal-
meterol/ﬂuticasone plus SABA. In the STAY study, 2760 patients
received budesonide/formoterol (80/4.5 mg bd) plus SABA, bude-
sonide (320 mg bd) plus SABA or budesonide/formoterol mainte-
nance and reliever therapy (80/4.5 mg bd) for 12months to establish
whether the latter approach could improve current control and
reduce future risk [14]. Treatment with budesonide/formoterol for
maintenance and relief improved current asthma control compared
with a higher dose of budesonide plus SABA or the same dose of
budesonide/formoterol plus SABA, as demonstrated by a signiﬁcant
reduction in daytime and night-time reliever use and night-time
symptom scores (all p < 0.001). Additionally, morning peak expi-
ratory ﬂow was signiﬁcantly improved versus the other treatment
regimens (Fig. 3A; p < 0.001), and the rate of severe exacerbations
was signiﬁcantly reduced compared with both control arms
(Fig. 4A; p < 0.001).
The effect of budesonide/formoterol maintenance and reliever
therapy (160/4.5 mg bd), a higher dose of budesonide/formoterol
(320/9 mg bd) plus SABA or salmeterol/ﬂuticasone (50/250 mg bd)
plus SABA on overall asthma control was assessed in the COMPASS
study, which included 3335 patients [16]. Asthma Control Ques-
tionnaire scores over the duration of the study were similar for all
three treatment groups (Fig. 3B), indicating that use of budesonide/
formoterol for maintenance and relief was as effective as the higher
dose of budesonide/formoterol plus SABA or salmeterol/ﬂuticasone
plus SABA at improving current asthma control. This regimen also
resulted in the lowest rate of severe exacerbations (Fig. 4B). Similar
results were observed in the AHEAD trial, in which 2309 patients
were treated with salmeterol/ﬂuticasone (50/500 mg bd) plus SABA
or budesonide/formoterol maintenance and reliever therapy (320/
9 mg bd) [17]. In this study, current control was improved to a
similar extent in both groups, as indicated by comparable changes
in ACQ-5 scores from baseline (Fig. 3C). Severe exacerbations
occurred less frequently among patients treated with budesonide/
formoterol for maintenance and relief compared with salmeterol/
ﬂuticasone plus SABA (Fig. 4C; p < 0.05).
The STAY, COMPASS and AHEAD studies have demonstrated how
the use of budesonide/formoterol as maintenance and reliever
therapy provides current control and minimises future risk without
utilising the high maintenance doses of ICS that are sometimes
required with other treatment regimens [3,4,14,16,17]. Indeed, pa-
tients using budesonide/formoterol as maintenance and reliever
therapy in the COMPASS study had a lowermean ICS load than those
receiving ahigherdoseof budesonide/formoterol plus SABA, despite
using the ICS/LABA combination as reliever medication [16]. How-
ever, concern has been expressed that budesonide/formoterol re-
liever medication could increase the risk of adverse events due to
both short-term and cumulative exposure to treatment.
Fig. 3. Current asthma control with twice-daily treatment in STAY (A) [14], COMPASS (B) [16] and AHEAD (C) [17]. ACQ-5, Asthma Control Questionnaire (5-item version); BUD,
budesonide; FLU, ﬂuticasone; FORM, formoterol; MRT, maintenance and reliever therapy; PEF, peak expiratory ﬂow; SABA, short-acting b2-agonist; SAL, salmeterol.
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et al. to assess the riskebeneﬁt proﬁle of the maintenance and re-
liever therapy approach [28]. In this study, patients received twice-
daily maintenance therapy with budesonide/formoterol (400/12 mg
bd metered dose, equivalent to 320/9 mg bd delivered dose) plus
either budesonide/formoterol or SABA as reliever medication;
electronicmonitoringwasused to assess patterns ofmedicationuse.
As could be expected with such a trial design, patients receiving
budesonide/formoterol for both maintenance and relief had a
greater exposure to ICS than those using a SABA, and these patients
had signiﬁcantly fewer days in which they received zero actuations
of budesonide/formoterol (p ¼ 0.022). As budesonide/formoterol
maintenance and reliever therapy reduced severe exacerbations
compared with budesonide/formoterol plus SABA, patients treated
with this regimen had a lower oral corticosteroid exposuremeaning
that the overall corticosteroid burden was similar between the two
groups. The frequency of adverse events was also similar between
the two groups. Budesonide/formoterol maintenance and reliever
therapy therefore has a favourable riskebeneﬁt proﬁle in adults atrisk of severe asthma exacerbations.
In contrast to budesonide/formoterol, the use of beclometasone/
formoterol maintenance and reliever therapy has only been
investigated in one study, a 48-week, multicentre, double-blind,
randomised, controlled trial that included 1714 patients with
asthma that was not fully controlled [19]. In this study, the time to
ﬁrst exacerbation, deﬁned as admission to hospital or visit to an
emergency department, or use of systemic steroids for 3
consecutive days, was signiﬁcantly increased with beclometasone/
formoterol maintenance and reliever therapy compared with
beclometasone/formoterol plus as-needed salbutamol (209 days
and 134 days, respectively), corresponding to a 36% reduction in
risk (HR 0.64 [95% CI 0.49 to 0.82]; p ¼ 0.0005); both treatments
were well tolerated. Consequently, this study demonstrated that
the use of beclometasone/formoterol for maintenance and relief
was effective at reducing future risk in patients with moderate-to-
severe asthma. However, improvements in mean FEV1 and asthma
symptom scores were not signiﬁcantly different between the
treatment groups.
Fig. 4. Rate of severe asthma exacerbations with twice-daily treatment in STAY (A) [14], COMPASS (B) [16] and AHEAD (C) [17]. aSevere asthma exacerbations were deﬁned as
deterioration in asthma resulting in: hospitalisation/ER treatment, oral steroid treatment (or an increase in ICS [via a separate inhaler] and/or other additional treatment for children
aged 4e11 years), or morning PEF of 70% or less of baseline on two consecutive days in STAY (A); hospitalisation/ER treatment, or the need for OCS for 3 days (as judged by the
investigator) in COMPASS (B); hospitalisation/ER treatment and/or OCS treatment for 3 days in AHEAD (C). BUD, budesonide; ER, emergency room; FLU, ﬂuticasone; FORM,
formoterol; ICS, inhaled corticosteroid; MRT, maintenance and reliever therapy; OCS, oral corticosteroid; PEF, peak expiratory ﬂow; SABA, short-acting b2-agonist; SAL, salmeterol.
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In addition to the studies discussed above, the use of budeso-
nide/formoterol as maintenance and reliever therapy has been
assessed in over 23,000 patients as part of four real-world studies
that included comparisons with salmeterol/ﬂuticasone or conven-
tional best practice and an evaluation of a range of doses
[18,29e31]. Budesonide/formoterol maintenance and reliever
therapy was shown to improve asthma control and reduce the
frequency of exacerbations compared with either salmeterol/ﬂuti-
casone or conventional best practice [18,29]. Patients treated with
budesonide/formoterol for maintenance and relief received a
reduced overall mean daily dose of ICS compared with conven-
tional best practice [29], and oral corticosteroid use was also lower
than with salmeterol/ﬂuticasone plus SABA or conventional best
practice [18,29]. Interestingly, for patients treated with twice-daily
budesonide/formoterol maintenance and reliever therapy at doses
of 80/4.5 mg, 160/4.5 mg or 320/9 mg, reliever use was low irre-
spective of the dose received [31].4.3. ICS/LABA maintenance and reliever therapy: airway
inﬂammation and remodelling
As the use of ICS/LABA for both maintenance and relief may lead
to a reduction in the dose of ICS required to maintain stable disease
[34], concerns have previously been raised that this approach may
reduce the frequency of exacerbations without controlling airway
inﬂammation and remodelling [11,35]. In a 12-month, parallel-
group, randomised study, patients were treated with budesonide/
formoterol maintenance and reliever therapy (160/4.5 mg bd;
delivered dose) or both budesonide/formoterol (320/9 mg bd) and
budesonide (320 mg bd) plus SABA in order to determine if the
lower maintenance dose of budesonide used in the maintenance
and reliever therapy approach had an effect on airway eosinophils
and remodelling [11]. Patients receiving budesonide/formoterol for
maintenance and relief had signiﬁcantly higher numbers of sputum
and bronchial biopsy eosinophils than those in the comparator arm.
However, these changes were relatively small and were not clini-
cally meaningful, despite the very high dose of budesonide used inthe comparator arm. Indeed, these variances were not associated
with differences in exacerbation rate, lung function or changes in
the fraction of exhaled nitric oxide. In addition, budesonide/for-
moterol maintenance and reliever therapy reduced airway
remodelling as effectively as the high dose of budesonide/for-
moterol plus SABA, as indicated by the lack of between-group dif-
ferences in reduction of reticular basement membrane thickness
over 12 months.5. Conclusions
In the pivotal FACET study, a lower dose of budesonide/for-
moterol improved current asthma control compared with a higher
dose of budesonide alone, although the lower dose of budesonide/
formoterol was associated with a smaller reduction in the exacer-
bation risk compared with a higher dose of budesonide alone [3].
Similarly, the GOAL study showed that addition of salmeterol to
ﬂuticasone improved health status and exacerbation risk compared
with ﬂuticasone alone, although it is not known whether this
approach is more beneﬁcial than increasing the dose of ﬂuticasone
monotherapy [4]. The use of ICS/LABA maintenance and reliever
therapy provides an alternative strategy to ﬁxed-dose ICS/LABA
maintenance therapy plus SABA, reducing the frequency of exac-
erbations and improving asthma control in patients with previ-
ously poorly controlled asthma and a history of exacerbations.
While one clinical study has demonstrated that beclometasone/
formoterol maintenance and reliever therapy is more effective at
reducing asthma exacerbations than beclometasone/formoterol
plus SABA [19], there is a large body of evidence to show that
treatment with budesonide/formoterol maintenance and reliever
therapy improves both current control and future risk compared
with ICS/LABA plus SABA or a higher dose of budesonide alone
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